Zobrazeno 1 - 10 of 22 pro vyhledávání: '"Susanne Famulla"'
1
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes
Autor: Parag Garhyan, Edward Pratt, Oliver Klein, Susanne Famulla, Eric Zijlstra, Amy Lalonde, Monica Swinney, Christof Kazda, Eyal Dassau
Publikováno v: Journal of Diabetes Science and Technology. 17:274-282
Background: We evaluated the effect of meloxicam on insulin lispro pharmacokinetics and glucose pharmacodynamics over 10 days of continuous subcutaneous insulin infusion (CSII) at one infusion site in people with type 1 diabetes (T1D). Method: This p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b78aaa8e52847a14c93f7e7b302b68e
https://doi.org/10.1177/19322968221145200
Zobrazit plný text záznamu
4
197-OR: ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram), Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D
Autor: Claire Mégret, You-Ping Chan, Rosy Eloy, Grit Andersen, J. Hans DeVries, Grégory Meiffren, Olivier Soula, Martin Gaudier, Cyril Seroussi, Tim Heise, Susanne Famulla
Publikováno v: Diabetes. 70
ADO09 is a co-formulation of Pram and insulin A21G developed to deliver the positive effects of Pram without additional injections. This double-blind randomized cross-over trial investigated the effects of pre-meal ADO09 vs. insulin aspart (ASP) on m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::344b58e8f9605e9d2046b5ae4726d3b5
https://doi.org/10.2337/db21-197-or
Zobrazit plný text záznamu
6
ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes
Autor: Grégory Meiffren, Grit Andersen, J. Hans DeVries, Olivier Soula, Susanne Famulla, Richard Charvet, Martin Gaudier, Tim Heise, Aymeric Ranson, Rosy Eloy, You-Ping Chan, Cyril Seroussi
Publikováno v: Diabetes, obesity & metabolism, 23(4), 961-970. Wiley-Blackwell
Aim: To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes. Methods: At three dosing vis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7bd276e57e5cbc9a4303b6b2f02c80d
https://pubmed.ncbi.nlm.nih.gov/33336850
Zobrazit plný text záznamu
8
112-LB: ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)
Autor: Tim Heise, J. Hans DeVries, Claire Mégret, Grégory Meiffren, Martin Gaudier, Rosy Eloy, Cyril Seroussi, Olivier Soula, Susanne Famulla, You-Ping Chan, Grit Andersen
Publikováno v: Diabetes. 69
ADO09 is a co-formulation of PRAM and insulin A21G developed to leverage the beneficial effects of PRAM on post-prandial glucose without additional injections. This double-blind randomized cross-over trial studied pre-meal ADO09 vs. Novolog® over 24
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c6f5a95073baba46b671a1331666759
https://doi.org/10.2337/db20-112-lb
Zobrazit plný text záznamu
9
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
Autor: Hanne Haahr, Tim Heise, Kadriye Kaplan, Marianne Nørskov, Susanne Famulla, Leszek Nosek
Publikováno v: Diabetes, Obesity & Metabolism
Aim To compare day-to-day and within-day variability in glucose-lowering effect between insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar-U300) in type 1 diabetes. Materials and methods In this double-blind, crossover study, patients were
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be32a50eb0c8a338ebfb3b1fd4dfd8f6
https://doi.org/10.1111/dom.12938
Zobrazit plný text záznamu
10
Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)
Autor: Stefan Kaspers, Jens Eilbracht, Nima Soleymanlou, Dietmar Neubacher, Hans-Juergen Woerle, Susanne Famulla, Uli C. Broedl, Thomas R. Pieber
Publikováno v: Diabetes Technology & Therapeutics. 19:49-60
We evaluated the effect of empagliflozin as adjunct to insulin on 24-h glucose exposure and variability in patients with type 1 diabetes.Patients (N = 75) with HbAEmpagliflozin reduced hourly mean glucose area under the median curve over 24 h versus
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a63f21e32fbf146a745dbd92c010d4
https://doi.org/10.1089/dia.2016.0261
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje